NYSE · RVTY
Healthcare · Medical - Diagnostics & Research
$143.31
Down-$1.20 (-0.84%)
Updated Sep 24, 2026, 1:35 AM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
RVTY closed at $143.31 after 19 trading sessions, up 13.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $143.12 | $144.77 | $141.71 | $143.31 | 2.87M |
| Sep 21, 2026 | $144.53 | $145.545 | $142.30 | $143.59 | 2.06M |
| Sep 18, 2026 | $146.50 | $146.885 | $142.45 | $143.45 | 3.32M |
| Sep 17, 2026 | $147.61 | $149.52 | $145.215 | $146.73 | 2.75M |
| Sep 16, 2026 | $140.88 | $147.50 | $140.20 | $145.73 | 3.4M |
| Sep 15, 2026 | $128.67 | $140.22 | $128.67 | $140.19 | 3.69M |
| Sep 14, 2026 | $124.69 | $128.70 | $123.95 | $128.49 | 1.9M |
| Sep 11, 2026 | $122.40 | $124.65 | $121.61 | $124.31 | 1.15M |
| Sep 10, 2026 | $122.77 | $123.23 | $120.895 | $120.94 | 1.34M |
| Sep 9, 2026 | $125.77 | $126.655 | $121.20 | $123.85 | 1.88M |
| Sep 8, 2026 | $128.50 | $129.54 | $126.89 | $127.08 | 1.5M |
| Sep 4, 2026 | $130.03 | $131.70 | $129.56 | $130.22 | 1.18M |
| Sep 3, 2026 | $132.45 | $133.00 | $127.78 | $130.63 | 1.82M |
| Sep 2, 2026 | $125.94 | $131.75 | $125.94 | $130.94 | 2.1M |
| Sep 1, 2026 | $127.46 | $128.18 | $125.49 | $126.59 | 3.06M |
| Aug 31, 2026 | $127.34 | $128.815 | $125.456 | $128.67 | 1.63M |
| Aug 28, 2026 | $128.57 | $130.07 | $127.26 | $128.80 | 1.58M |
| Aug 27, 2026 | $126.53 | $129.80 | $126.50 | $129.71 | 1.93M |
| Aug 26, 2026 | $123.29 | $126.90 | $123.29 | $126.35 | 1.16M |
The latest Smart Investors Daily articles mentioning RVTY.
RVTY research
Company profile and research snapshot.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | Keybanc | Overweight | — |
| Sep 1, 2026 | RBC Capital | Sector Perform | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Bernstein | Market Perform | — |
No generated briefing is available yet.
Benzinga · Sep 16, 2026
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of $16.24 billion.
Yahoo · Sep 15, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.
CNBC · Sep 15, 2026
These are the stocks posting the largest moves midday.
SeekingAlpha · Sep 15, 2026
Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RVTY.
